Frank D'alessandro, MD
Endocrinology, Diabetes & Metabolism · North Providence, RINPI 1447317730
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $163,699 of the $193,229 with a category attached, or 84.7%. 39 manufacturers reported payments, led by Boehringer Ingelheim at 32.7% of the total. Reporting peaked in 2019 at $38,766 and has fallen 62.1% since, to $14,685 in 2025. Among endocrinology, diabetes & metabolism clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 917 payments — averaging $210.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$63K
- Sanofi-aventis U.S. LLC$45K
- Lilly USA, LLC$40K
- Xeris Pharmaceuticals, Inc.$17K
- Johnson & Johnson$10K
- AstraZeneca$7K
- plus $10K from 33 others
What the payments were for
- Consulting fees$10,8606%
- Speaking & faculty fees$163,69985%
- Travel & lodging$2,6421%
- Food & beverage$15,9438%
- Education$260%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 182 | $63,123 |
| Sanofi-aventis U.S. LLC | 118 | $45,027 |
| Lilly USA, LLC | 105 | $40,243 |
| Xeris Pharmaceuticals, Inc. | 28 | $17,378 |
| Johnson & Johnson | 38 | $9,995 |
| AstraZeneca(2 entities) | 20 | $7,004 |
| Mannkind Corporation | 59 | $3,937 |
| Novo Nordisk | 128 | $1,791 |
| Abbott | 46 | $690 |
| Cequr Corporation | 3 | $526 |
| Bayer | 17 | $462 |
| Antares Pharma, Inc. | 18 | $410 |
| Tolmar, Inc. | 20 | $344 |
| AbbVie | 15 | $309 |
| Dexcom, Inc. | 17 | $301 |
| Amneal Pharmaceuticals LLC | 34 | $284 |
| Medtronic(2 entities) | 6 | $212 |
| Corcept Therapeutics | 4 | $182 |
| Merck | 20 | $156 |
| Insulet Corporation | 1 | $141 |
| Lexicon Pharmaceuticals, Inc. | 5 | $102 |
| GSK | 5 | $89 |
| Lundbeck LLC | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $52 |
| Ascendis Pharma Endocrinology Inc | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Amgen | 2 | $46 |
| Shire North American Group Inc | 2 | $45 |
| Pfizer | 2 | $33 |
| Aytu Biopharma, Inc. | 2 | $30 |
| Eisai Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Highridge Medical LLC | 1 | $18 |
| EBI, LLC | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Valeritas, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$97,580
- TOUJEO$29,859
- SOLIQUA 100/33$24,639
- INVOKANA$9,576
- GVOKE HYPOPEN$8,625
- GVOKE PFS$8,294
- FARXIGA$6,760
- AFREZZA$3,195
- CeQur Simplicity$450
- Kerendia$235
- Ozempic$231
- Omnipod$141
- FREESTYLE LIBRE 3$133
- DEXCOM G6 TRANSMITTER$118
- Signia$117
- Korlym$110
How this compares
$193,229 in reported general payments places this provider in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 830 | $846,415 |
| JardianceEmpagliflozin | 1,089 | $750,242 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 202 | $176,537 |
| TrulicityDulaglutide | 99 | $91,369 |
| Tresiba Flextouch U-200Insulin Degludec | 76 | $62,435 |
| MounjaroTirzepatide | 60 | $59,566 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 109 | $49,953 |
| FarxigaDapagliflozin Propanediol | 55 | $45,049 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $44,666 |
| AfrezzaInsulin Regular, Human | 20 | $38,132 |
| Humalog Kwikpen U-100Insulin Lispro | 177 | $35,345 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $27,184 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $23,619 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $22,573 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $22,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,791 | $846,415830 claims |
| Boehringer IngelheimJardiance, Tradjenta | $63,123 | $759,1441,105 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $40,243 | $152,899175 claims |
| AstraZenecaFarxiga | $7,004 | $45,04955 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $45,027 | $44,66641 claims |
| Mannkind CorporationAfrezza | $3,937 | $38,13220 claims |
| AbbVieSynthroid | $309 | $10,860146 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $284 | $9,270468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in North Providence
- Frank DalessandroNorth Providence$389
- Robert DobrzynskiProvidence$245K
- Ricardo Correa MarquezEast Providence$94K
- Robert SmithProvidence$80K
- Sudhir BansalWarwick$38K
- Joseph TucciProvidence$30K
- Judith GilmoreWakefield$11K
- Stephanie CurryJohnston$8K
- Beatriz DemoranvilleWarwick$5K
- Raquel CarneiroRiverside$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.